These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 34002914)

  • 1. Uptake of interferon-free DAA therapy among HCV-infected decompensated cirrhosis patients and evidence for decreased mortality.
    McDonald SA; Barclay ST; Innes HA; Fraser A; Hayes PC; Bathgate A; Dillon JF; Went A; Goldberg DJ; Hutchinson SJ
    J Viral Hepat; 2021 Sep; 28(9):1246-1255. PubMed ID: 34002914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
    Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
    J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population impact of direct-acting antiviral treatment on new presentations of hepatitis C-related decompensated cirrhosis: a national record-linkage study.
    Hutchinson SJ; Valerio H; McDonald SA; Yeung A; Pollock K; Smith S; Barclay S; Dillon JF; Fox R; Bramley P; Fraser A; Kennedy N; Gunson RN; Templeton K; Innes H; McLeod A; Weir A; Hayes PC; Goldberg D
    Gut; 2020 Dec; 69(12):2223-2231. PubMed ID: 32217640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosis.
    McDonald SA; Pollock KG; Barclay ST; Goldberg DJ; Bathgate A; Bramley P; Dillon JF; Fraser A; Innes HA; Kennedy N; Morris J; Went A; Hayes PC; Hutchinson SJ
    J Viral Hepat; 2020 Mar; 27(3):270-280. PubMed ID: 31696575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment rates and factors associated with direct-acting antiviral therapy for insured patients with hepatitis C-related hepatocellular carcinoma - A real-world nationwide study.
    Kam LY; Yeo YH; Ji F; Henry L; Cheung R; Nguyen MH
    Aliment Pharmacol Ther; 2024 Feb; 59(3):350-360. PubMed ID: 37937485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognosis of 1169 hepatitis C chronically infected patients with decompensated cirrhosis in the predirect-acting antiviral era.
    McDonald SA; Innes HA; Aspinall E; Hayes PC; Alavi M; Valerio H; Goldberg DJ; Hutchinson SJ
    J Viral Hepat; 2017 Apr; 24(4):295-303. PubMed ID: 27885753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Direct-acting Antivirals on Hepatocellular Carcinoma and Mortality Among Medicaid Beneficiaries With Hepatitis C.
    Jiang X; Song HJ; Chang CY; Wilson DL; Lo-Ciganic WH; Park H
    Med Care; 2023 Aug; 61(8):505-513. PubMed ID: 37223993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvements in liver transplant outcomes in patients with HCV/HIV coinfection after the introduction of direct-acting antiviral therapies.
    Shimada S; Ivanics T; Kitajima T; Shamaa T; Rizzari M; Collins K; Yoshida A; Abouljoud M; Moonka D; Zhang J; Lu M; Nagai S
    Transpl Infect Dis; 2022 Apr; 24(2):e13808. PubMed ID: 35157334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry.
    Belli LS; Perricone G; Adam R; Cortesi PA; Strazzabosco M; Facchetti R; Karam V; Salizzoni M; Andujar RL; Fondevila C; De Simone P; Morelli C; Fabregat-Prous J; Samuel D; Agarwaal K; Moreno Gonzales E; Charco R; Zieniewicz K; De Carlis L; Duvoux C;
    J Hepatol; 2018 Oct; 69(4):810-817. PubMed ID: 29940268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study.
    Singer AW; Reddy KR; Telep LE; Osinusi AO; Brainard DM; Buti M; Chokkalingam AP
    Aliment Pharmacol Ther; 2018 May; 47(9):1278-1287. PubMed ID: 29516535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: An international study.
    Alavi M; Janjua NZ; Chong M; Grebely J; Aspinall EJ; Innes H; Valerio HM; Hajarizadeh B; Hayes PC; Krajden M; Amin J; Law MG; George J; Goldberg DJ; Hutchinson SJ; Dore GJ
    J Hepatol; 2018 Mar; 68(3):393-401. PubMed ID: 29107152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy.
    Flemming JA; Kim WR; Brosgart CL; Terrault NA
    Hepatology; 2017 Mar; 65(3):804-812. PubMed ID: 28012259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
    Bailly F; Pradat P; Virlogeux V; Zoulim F
    Dig Dis; 2015; 33(4):613-23. PubMed ID: 26159282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In the Era of Direct-Acting Antivirals, Liver Transplant Delisting Due to Clinical Improvement for Hepatitis C Remains Infrequent.
    Bittermann T; Reddy KR
    Clin Gastroenterol Hepatol; 2021 Nov; 19(11):2389-2397.e2. PubMed ID: 32971230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C Virus (HCV) Treatment With Directly Acting Agents Reduces the Risk of Incident Diabetes: Results From Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES).
    Butt AA; Yan P; Aslam S; Shaikh OS; Abou-Samra AB
    Clin Infect Dis; 2020 Mar; 70(6):1153-1160. PubMed ID: 30977808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aminopyrine breath test predicts liver-related events and death in HCV-related cirrhosis on SVR after DAA therapy.
    Petta S; Rini F; Calvaruso V; Cammà C; Ciminnisi S; Di Marco V; Giannini EG; Grimaudo S; Maria Pipitone R; Craxì A
    Liver Int; 2020 Mar; 40(3):530-538. PubMed ID: 31507057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of chronic HCV genotype 1 coinfection.
    Boesecke C; Rockstroh JK
    Curr HIV/AIDS Rep; 2015 Sep; 12(3):326-35. PubMed ID: 26228050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens.
    Tayyab GUN; Rasool S; Nasir B; Rubi G; Abou-Samra AB; Butt AA
    BMC Gastroenterol; 2020 Apr; 20(1):93. PubMed ID: 32252635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of all-oral direct-acting antivirals in hepatitis C virus-infected patients with substance use disorders.
    Jiang X; Song HJ; Wang W; Henry L; Childs-Kean LM; Re VL; Park H
    J Manag Care Spec Pharm; 2021 Jul; 27(7):873-881. PubMed ID: 34185563
    [No Abstract]   [Full Text] [Related]  

  • 20. Reduced Incidence of Hepatic Encephalopathy and Higher Odds of Resolution Associated With Eradication of HCV Infection.
    Tapper EB; Parikh ND; Green PK; Berry K; Waljee AK; Moon AM; Ioannou GN
    Clin Gastroenterol Hepatol; 2020 May; 18(5):1197-1206.e7. PubMed ID: 31589975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.